| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BMS-536924 | GDSC1000 | pan-cancer | AAC | 0.018 | 0.6 |
| mRNA | CD-437 | CTRPv2 | pan-cancer | AAC | -0.017 | 0.6 |
| mRNA | Repligen 136 | CTRPv2 | pan-cancer | AAC | -0.02 | 0.6 |
| mRNA | CBB-1007 | CTRPv2 | pan-cancer | AAC | 0.03 | 0.6 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.02 | 0.6 |
| mRNA | BRD-K41334119 | CTRPv2 | pan-cancer | AAC | -0.039 | 0.6 |
| mRNA | BRD-K09587429 | CTRPv2 | pan-cancer | AAC | 0.021 | 0.6 |
| mRNA | ML006 | CTRPv2 | pan-cancer | AAC | 0.02 | 0.6 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.025 | 0.6 |
| mRNA | CHIR-99021 | CTRPv2 | pan-cancer | AAC | 0.017 | 0.6 |